If you have been reading about Reference standard and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-29. Numbers and descriptions here follow the published literature rather than marketing material.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
The genetic code was once believed to be universal: a codon would code for the same amino acid regardless of the organism or source. However, it is now agreed that the genetic code evolves, resulting in discrepancies in how a codon is translated depending on the genetic source. For example, in 1981, it was discovered that the use of codons AUA, UGA, AGA and AGG by the coding system in mammalian mitochondria differed from the universal code. Stop codons can also be affected: in ciliated protozoa, the universal stop codons UAA and UAG code for glutamine. Four novel alternative genetic codes (numbered here 34–37) were discovered in bacterial genomes by Shulgina and Eddy, revealing the first sense codon changes in bacteria. The following table displays these alternative codons.
Fluid dynamics is a subdiscipline of fluid mechanics that deals with fluid flow—the science of liquids and gases in motion. Fluid dynamics offers a systematic structure—which underlies these practical disciplines—that embraces empirical and semi-empirical laws derived from flow measurement and used to solve practical problems. The solution to a fluid dynamics problem typically involves calculating various properties of the fluid, such as velocity, pressure, density, and temperature, as functions of space and time. It has several subdisciplines itself, including aerodynamics (the study of air and other gases in motion) and hydrodynamics (the study of liquids in motion). Fluid dynamics has a wide range of applications, including calculating forces and moments on aircraft, determining the mass flow rate of petroleum through pipelines, predicting evolving weather patterns, understanding nebulae in interstellar space and modeling explosions. Some fluid-dynamical principles are used in traffic engineering and crowd dynamics.
Albany is in the central part of Oregon's most populated region, the Willamette Valley. The city rests along the confluence of the Calapooia and Willamette rivers, and although most of Albany falls within Linn County, a smaller portion of the city rests to the north of its downtown on the west bank of the Willamette River in Benton County. According to the United States Census Bureau, the city has a total area of 17.75 square miles (45.97 km2), of which 17.54 square miles (45.43 km2) is land and 0.21 square miles (0.54 km2) is water. Albany has 21.7 square miles (56 km2) within its urban growth boundary. Throughout the city limits and urban growth area, there are limited hills; the city is one of the lowest points along the Willamette Valley, with elevations ranging 180 to 430 feet (55 to 131 m) above sea level. The North Albany district has the most variable elevation, while the downtown and southern end of town have little elevation change throughout.
Sources: en.wikipedia.org
==== New Zealand ==== Sildenafil was reclassified in New Zealand in 2014 so it could be bought over the counter from a pharmacist. It is thought that this reduced sales over the Internet and was safer as males could be referred for medical advice if appropriate.
A peculiarly British practice was the "loose-coupled" freight train, operated by the locomotive crew and a "guard" at the rear of the train, the successor to the brakesman of earlier times. That train type used three-link chain couplings for traction and side buffers to accept pushing forces but, since such trains were not fitted with an automatic through-train braking system, there were no pipes to connect between the vehicles. The last vehicle of the train was a heavily ballasted guard's van with its brakes controllable by a handwheel operated by the guard. The slack between vehicles coupled in this way was very convenient when starting heavy trains with a relatively low-powered locomotive on the level or on a rising gradient. On the driver's command the guard would apply his brake as hard as possible. The driver would then gently reverse to close up the wagons on to their buffers. Then the locomotive would be driven ahead, picking up the load wagon by wagon, thus giving an easy start up the gradient. Wagons of that era did not have roller bearings and the grease-lubricated plain bearings exerted considerable resistance to motion, especially on a cold day, so starting wagon-by-wagon in this way allowed the locomotive to move off with low initial resistance. The disadvantage of that convenience was that the guard could be badly thrown about as the train changed speed due to the inter-wagon gaps opening or closing. In the worst case, the jerks could break a coupling or cause a derailment.
== History == Pachamanca dates back to pre-incan times, used in religious festivities and celebrations. It was made as a way to give back to the Incan earth goddess Pachamama. In certain parts of the country, this dish has a godmother and a godfather who are in charge of placing a cross and flowers on the buried food, which is a traditional custom in Andean festivals and celebrations. The definition of pachamanca is the combination of the words pacha and manca, pacha (earth) and manca (cooking pot). The heated stones symbolize Inti, the Sun God, and the source of warmth. The tradition of burying the food underground signifies a return to the womb of Pachamama. A band of musicians usually accompanies the proceedings, while chicha and beer are also served.
=== EC 2.3.1: Transferring groups other than amino-acyl groups === EC 2.3.1.1: amino-acid N-acetyltransferase EC 2.3.1.2: imidazole N-acetyltransferase EC 2.3.1.3: glucosamine N-acetyltransferase EC 2.3.1.4: glucosamine-phosphate N-acetyltransferase EC 2.3.1.5: arylamine N-acetyltransferase EC 2.3.1.6: choline O-acetyltransferase EC 2.3.1.7: carnitine O-acetyltransferase EC 2.3.1.8: phosphate acetyltransferase EC 2.3.1.9: acetyl-CoA C-acetyltransferase EC 2.3.1.10: hydrogen-sulfide S-acetyltransferase EC 2.3.1.11: thioethanolamine S-acetyltransferase EC 2.3.1.12: dihydrolipoyllysine-residue acetyltransferase EC 2.3.1.13: glycine N-acyltransferase EC 2.3.1.14: glutamine N-phenylacetyltransferase EC 2.3.1.15: glycerol-3-phosphate O-acyltransferase EC 2.3.1.16: acetyl-CoA C-acyltransferase EC 2.3.1.17: aspartate N-acetyltransferase EC 2.3.1.18: galactoside O-acetyltransferase EC 2.3.1.19: phosphate butyryltransferase EC 2.3.1.20: diacylglycerol O-acyltransferase EC 2.3.1.21: carnitine O-palmitoyltransferase EC 2.3.1.22: 2-acylglycerol O-acyltransferase EC 2.3.1.23: 1-acylglycerophosphocholine O-acyltransferase EC 2.3.1.24: sphingosine N-acyltransferase EC 2.3.1.25: plasmalogen synthase EC 2.3.1.26: sterol O-acyltransferase EC 2.3.1.27: cortisol O-acetyltransferase EC 2.3.1.28: chloramphenicol O-acetyltransferase EC 2.3.1.29: glycine C-acetyltransferase EC 2.3.1.30: serine O-acetyltransferase EC 2.3.1.31: homoserine O-acetyltransferase EC 2.3.1.32: lysine N-acetyltransferase EC 2.3.1.33: histidine N-acetyltransferase EC 2.3.1.34: D-tryptophan N-acetyltransferase EC 2.3.1.35: glutamate N-acetyltransferase EC 2.3.1.36: D-amino-acid N-acetyltransferase EC 2.3.1.37: 5-aminolevulinate synthase EC 2.3.1.38: [acyl-carrier-protein] S-acetyltransferase EC 2.3.1.39: [acyl-carrier-protein] S-malonyltransferase EC 2.3.1.40: acyl-[acyl-carrier-protein]—phospholipid O-acyltransferase EC 2.3.1.41: β-ketoacyl-[acyl-carrier-protein] synthase I EC 2.3.1.42: glycerone-phosphate O-acyltransferase EC 2.3.1.43: phosphatidylcholine—sterol O-acyltransferase EC 2.3.1.44: N-acetylneuraminate 4-O-acetyltransferase EC 2.3.1.45: N-acetylneuraminate 7-O(or 9-O)-acetyltransferase EC 2.3.1.46: homoserine O-succinyltransferase EC 2.3.1.47: 8-amino-7-oxononanoate synthase EC 2.3.1.48: histone acetyltransferase EC 2.3.1.49: deacetyl-(citrate-(pro-3S)-lyase) S-acetyltransferase EC 2.3.1.50: serine C-palmitoyltransferase EC 2.3.1.51: 1-acylglycerol-3-phosphate O-acyltransferase EC 2.3.1.52: 2-acylglycerol-3-phosphate O-acyltransferase EC 2.3.1.53: phenylalanine N-acetyltransferase EC 2.3.1.54: formate C-acetyltransferase EC 2.3.1.55: identical to EC 2.3.1.82 EC 2.3.1.56: aromatic-hydroxylamine O-acetyltransferase EC 2.3.1.57: diamine N-acetyltransferase EC 2.3.1.58: 2,3-diaminopropionate N-oxalyltransferase EC 2.3.1.59: gentamicin 2′-N-acetyltransferase EC 2.3.1.60: gentamicin 3′-N-acetyltransferase EC 2.3.1.61: dihydrolipoyllysine-residue succinyltransferase EC 2.3.1.62: 2-acylglycerophosphocholine O-acyltransferase EC 2.3.1.63: 1-alkylglycerophosphocholine O-acyltransferase EC 2.3.1.64: agmatine N4-coumaroyltransferase EC 2.3.1.65: bile acid-CoA:amino acid N-acyltransferase EC 2.3.1.66: leucine N-acetyltransferase EC 2.3.1.67: 1-alkylglycerophosphocholine O-acetyltransferase EC 2.3.1.68: glutamine N-acyltransferase EC 2.3.1.69: monoterpenol O-acetyltransferase EC 2.3.1.70: deleted EC 2.3.1.71: glycine N-benzoyltransferase EC 2.3.1.72: indoleacetylglucose—inositol O-acyltransferase EC 2.3.1.73: diacylglycerol—sterol O-acyltransferase EC 2.3.1.74: chalcone synthase EC 2.3.1.75: long-chain-alcohol O-fatty-acyltransferase EC 2.3.1.76: retinol O-fatty-acyltransferase EC 2.3.1.77: triacylglycerol—sterol O-acyltransferase EC 2.3.1.78: heparan-α-glucosaminide N-acetyltransferase EC 2.3.1.79: maltose O-acetyltransferase EC 2.3.1.80: cysteine-S-conjugate N-acetyltransferase EC 2.3.1.81: aminoglycoside 3-N-acetyltransferase EC 2.3.1.82: aminoglycoside 6′-N-acetyltransferase EC 2.3.1.83: phosphatidylcholine—dolichol O-acyltransferase EC 2.3.1.84: alcohol O-acetyltransferase EC 2.3.1.85: fatty-acid synthase system EC 2.3.1.86: fatty-acyl-CoA synthase system EC 2.3.1.87: aralkylamine N-acetyltransferase EC 2.3.1.88: Now covered by EC 2.3.1.254, EC 2.3.1.255, EC 2.3.1.256, EC 2.3.1.257, EC 2.3.1.258 and EC 2.3.1.259 EC 2.3.1.89: tetrahydrodipicolinate N-acetyltransferase EC 2.3.1.90: β-glucogallin O-galloyltransferase EC 2.3.1.91: sinapoylglucose—choline O-sinapoyltransferase EC 2.3.1.92: sinapoylglucose—malate O-sinapoyltransferase EC 2.3.1.93: 13-hydroxylupinine O-tigloyltransferase EC 2.3.1.94: 6-deoxyerythronolide-B synthase EC 2.3.1.95: trihydroxystilbene synthase EC 2.3.1.96: glycoprotein N-palmitoyltransferase EC 2.3.1.97: glycylpeptide N-tetradecanoyltransferase EC 2.3.1.98: chlorogenate—glucarate O-hydroxycinnamoyltransferase EC 2.3.1.99: quinate O-hydroxycinnamoyltransferase EC 2.3.1.100: [myelin-proteolipid] O-palmitoyltransferase EC 2.3.1.101: formylmethanofuran—tetrahydromethanopterin N-formyltransferase EC 2.3.1.102: N6-hydroxylysine O-acetyltransferase EC 2.3.1.103: sinapoylglucose—sinapoylglucose O-sinapoyltransferase EC 2.3.1.104: The activity is covered by EC 2.3.1.25 EC 2.3.1.105: alkylglycerophosphate 2-O-acetyltransferase EC 2.3.1.106: tartronate O-hydroxycinnamoyltransferase EC 2.3.1.107: deacetylvindoline O-acetyltransferase EC 2.3.1.108: α-tubulin N-acetyltransferase EC 2.3.1.109: arginine N-succinyltransferase EC 2.3.1.110: tyramine N-feruloyltransferase EC 2.3.1.111: mycocerosate synthase EC 2.3.1.112: D-tryptophan N-malonyltransferase EC 2.3.1.113: anthranilate N-malonyltransferase EC 2.3.1.114: 3,4-dichloroaniline N-malonyltransferase EC 2.3.1.115: isoflavone-7-O-β-glucoside 6′′-O-malonyltransferase EC 2.3.1.116: flavonol-3-O-β-glucoside O-malonyltransferase EC 2.3.1.117: 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase EC 2.3.1.118: N-hydroxyarylamine O-acetyltransferase EC 2.3.1.119: Now covered by EC 2.3.1.199, EC 1.1.1.330, EC 4.2.1.134 and EC 1.3.1.93 EC 2.3.1.120: The reaction is due to EC 2.3.1.74 EC 2.3.1.121: 1-alkenylglycerophosphoethanolamine O-acyltransferase EC 2.3.1.122: trehalose O-mycolyltransferase EC 2.3.1.123: dolichol O-acyltransferase EC 2.3.1.124: Already listed as EC 2.3.1.20 EC 2.3.1.125: 1-alkyl-2-acetylglycerol O-acyltransferase EC 2.3.1.126: isocitrate O-dihydroxycinnamoyltransferase EC 2.3.1.127: ornithine N-benzoyltransferase EC 2.3.1.128: now classified as EC 2.3.1.266 and EC 2.3.1.267 EC 2.3.1.129: acyl-[acyl-carrier-protein]—UDP-N-acetylglucosamine O-acyltransferase EC 2.3.1.130: galactarate O-hydroxycinnamoyltransferase EC 2.3.1.131: glucarate O-hydroxycinnamoyltransferase EC 2.3.1.132: glucarolactone O-hydroxycinnamoyltransferase EC 2.3.1.133: shikimate O-hydroxycinnamoyltransferase EC 2.3.1.134: galactolipid O-acyltransferase EC 2.3.1.135: phosphatidylcholine—retinol O-acyltransferase EC 2.3.1.136: polysialic-acid O-acetyltransferase EC 2.3.1.137: carnitine O-octanoyltransferase EC 2.3.1.138: putrescine N-hydroxycinnamoyltransferase EC 2.3.1.139: ecdysone O-acyltransferase EC 2.3.1.140: rosmarinate synthase EC 2.3.1.141: galactosylacylglycerol O-acyltransferase EC 2.3.1.142: glycoprotein O-fatty-acyltransferase EC 2.3.1.143: β-glucogallin—tetrakisgalloylglucose O-galloyltransferase EC 2.3.1.144: anthranilate N-benzoyltransferase EC 2.3.1.145: piperidine N-piperoyltransferase EC 2.3.1.146: pinosylvin synthase EC 2.3.1.147: glycerophospholipid arachidonoyl-transferase (CoA-independent) EC 2.3.1.148: glycerophospholipid acyltransferase (CoA-dependent) EC 2.3.1.149: platelet-activating factor acetyltransferase EC 2.3.1.150: salutaridinol 7-O-acetyltransferase EC 2.3.1.151: 2,3′,4,6-tetrahydroxybenzophenone synthase EC 2.3.1.152: alcohol O-cinnamoyltransferase EC 2.3.1.153: anthocyanin 5-(6′′′-hydroxycinnamoyltransferase) EC 2.3.1.154: Now EC 2.3.1.176 EC 2.3.1.155: acetyl-CoA C-myristoyltransferase EC 2.3.1.156: phloroisovalerophenone synthase EC 2.3.1.157: glucosamine-1-phosphate N-acetyltransferase EC 2.3.1.158: phospholipid:diacylglycerol acyltransferase EC 2.3.1.159: acridone synthase EC 2.3.1.160: vinorine synthase EC 2.3.1.161: lovastatin nonaketide synthase EC 2.3.1.162: taxadien-5α-ol O-acetyltransferase EC 2.3.1.163: 10-hydroxytaxane O-acetyltransferase EC 2.3.1.164: isopenicillin-N N-acyltransferase EC 2.3.1.165: 6-methylsalicylic acid synthase EC 2.3.1.166: 2α-hydroxytaxane 2-O-benzoyltransferase EC 2.3.1.167: 10-deacetylbaccatin III 10-O-acetyltransferase EC 2.3.1.168: dihydrolipoyllysine-residue (2-methylpropanoyl)transferase EC 2.3.1.169: CO-methylating acetyl-CoA synthase EC 2.3.1.170: 6′-deoxychalcone synthase EC 2.3.1.171: anthocyanin 6′′-O-malonyltransferase EC 2.3.1.172: anthocyanin 5-O-glucoside 6′′′-O-malonyltransferase EC 2.3.1.173: flavonol-3-O-triglucoside O-coumaroyltransferase EC 2.3.1.174: 3-oxoadipyl-CoA thiolase EC 2.3.1.175: deacetylcephalosporin-C acetyltransferase EC 2.3.1.176: propanoyl-CoA C-acyltransferase EC 2.3.1.177: 3,5-dihydroxybiphenyl synthase EC 2.3.1.178: diaminobutyrate acetyltransferase EC 2.3.1.179: β-ketoacyl-[acyl-carrier-protein] synthase II EC 2.3.1.180: β-ketoacyl-[acyl-carrier-protein] synthase III EC 2.3.1.181: lipoyl(octanoyl) transferase EC 2.3.1.182: Now covered by EC 2.3.3.21 EC 2.3.1.183: phosphinothricin acetyltransferase EC 2.3.1.184: acyl-homoserine-lactone synthase EC 2.3.1.185: tropine acyltransferase EC 2.3.1.186: pseudotropine acyltransferase EC 2.3.1.187: acetyl-S-ACP:malonate ACP transferase EC 2.3.1.188: ω-hydroxypalmitate O-feruloyl transferase EC 2.3.1.189: mycothiol synthase EC 2.3.1.190: acetoin dehydrogenase EC 2.3.1.191: UDP-3-O-(3-hydroxyacyl)glucosamine N-acyltransferase EC 2.3.1.192: glycine N-phenylacetyltransferase EC 2.3.1.193: tRNAMetcytidine acetyltransferase EC 2.3.1.194: acetoacetyl-CoA synthase EC 2.3.1.195: (Z)-3-hexen-1-ol acetyltransferase EC 2.3.1.196: benzyl alcohol O-benzoyltransferase EC 2.3.1.197: dTDP-3-amino-3,6-dideoxy-α-D-galactopyranose 3-N-acetyltransferase EC 2.3.1.198: glycerol-3-phosphate 2-O-acyltransferase EC 2.3.1.199: very-long-chain 3-oxoacyl-CoA synthase EC 2.3.1.200: lipoyl amidotransferase EC 2.3.1.201: UDP-2-acetamido-3-amino-2,3-dideoxy-glucuronate N-acetyltransferase EC 2.3.1.202: UDP-4-amino-4,6-dideoxy-N-acetyl-β-L-altrosamine N-acetyltransferase EC 2.3.1.203: UDP-N-acetylbacillosamine N-acetyltransferase EC 2.3.1.204: octanoyl-[GcvH]:protein N-octanoyltransferase EC 2.3.1.205: fumigaclavine B O-acetyltransferase EC 2.3.1.206: 3,5,7-trioxododecanoyl-CoA synthase EC 2.3.1.207: β-ketodecanoyl-[acyl-carrier-protein] synthase EC 2.3.1.208: 4-hydroxycoumarin synthase EC 2.3.1.209: dTDP-4-amino-4,6-dideoxy-D-glucose acyltransferase EC 2.3.1.210: dTDP-4-amino-4,6-dideoxy-D-galactose acyltransferase EC 2.3.1.211: bisdemethoxycurcumin synthase EC 2.3.1.212: benzalacetone synthase EC 2.3.1.213: cyanidin 3-O-(6-O-glucosyl-2-O-xylosylgalactoside) 6′′′-O-hydroxycinnamoyltransferase EC 2.3.1.214: pelargonidin 3-O-(6-caffeoylglucoside) 5-O-(6-O-malonylglucoside) 4′′′-malonyltransferase EC 2.3.1.215: anthocyanin 3-O-glucoside 6-O-hydroxycinnamoyltransferase EC 2.3.1.216: 5,7-dihydroxy-2-methylchromone synthase EC 2.3.1.217: curcumin synthase EC 2.3.1.218: phenylpropanoylacetyl-CoA synthase EC 2.3.1.219: demethoxycurcumin synthase EC 2.3.1.220: 2,4,6-trihydroxybenzophenone synthase EC 2.3.1.221: noranthrone synthase EC 2.3.1.222: phosphate propanoyltransferase EC 2.3.1.223: 3-oxo-5,6-didehydrosuberyl-CoA thiolase EC 2.3.1.224: acetyl-CoA-benzylalcohol acetyltransferase EC 2.3.1.225: protein S-acyltransferase EC 2.3.1.226: carboxymethylproline synthase EC 2.3.1.227: GDP-perosamine N-acetyltransferase EC 2.3.1.228: isovaleryl-homoserine lactone synthase EC 2.3.1.229: 4-coumaroyl-homoserine lactone synthase EC 2.3.1.230: 2-heptyl-4(1H)-quinolone synthase EC 2.3.1.231: tRNAPhe {7-[3-amino-3-(methoxycarbonyl)propyl]wyosine37 -N}-methoxycarbonyltransferase EC 2.3.1.232: methanol O-anthraniloyltransferase EC 2.3.1.233: 1,3,6,8-tetrahydroxynaphthalene synthase EC 2.3.1.234: N6-L-threonylcarbamoyladenine synthase EC 2.3.1.235: tetracenomycin F2 synthase EC 2.3.1.236: 5-methylnaphthoic acid synthase EC 2.3.1.237: neocarzinostatin naphthoate synthase EC 2.3.1.238: monacolin J acid methylbutanoate transferase EC 2.3.1.239: 10-deoxymethynolide synthase EC 2.3.1.240: narbonolide synthase EC 2.3.1.241: Kdo2-lipid IVA lauroyltransferase EC 2.3.1.242: Kdo2-lipid IVA palmitoleoyltransferase EC 2.3.1.243: lauroyl-Kdo2-lipid IVA myristoyltransferase EC 2.3.1.244: 2-methylbutanoate polyketide synthase EC 2.3.1.245: 3-hydroxy-5-phosphooxypentane-2,4-dione thiolase EC 2.3.1.246: 3,5-dihydroxyphenylacetyl-CoA synthase EC 2.3.1.247: 3-keto-5-aminohexanoate cleavage enzyme EC 2.3.1.248: spermidine disinapoyl transferase EC 2.3.1.249: spermidine dicoumaroyl transferase EC 2.3.1.250: [Wnt protein] O-palmitoleoyl transferase EC 2.3.1.251: lipid IVA palmitoyltransferase EC 2.3.1.252: mycolipanoate synthase EC 2.3.1.253: phloroglucinol synthase EC 2.3.1.254: N-terminal methionine Nα-acetyltransferase NatB EC 2.3.1.255: N-terminal amino-acid Nα-acetyltransferase NatA EC 2.3.1.256: N-terminal methionine Nα-acetyltransferase NatC EC 2.3.1.257: N-terminal L-serine Nα-acetyltransferase NatD EC 2.3.1.258: N-terminal methionine Nα-acetyltransferase NatE EC 2.3.1.259: N-terminal methionine Nα-acetyltransferase NatF EC 2.3.1.260: tetracycline polyketide synthase EC 2.3.1.261: (4-hydroxyphenyl)alkanoate synthase EC 2.3.1.262: anthraniloyl-CoA anthraniloyltransferase EC 2.3.1.263: 2-amino-4-oxopentanoate thiolase EC 2.3.1.264: β-lysine N6-acetyltransferase EC 2.3.1.265: phosphatidylinositol dimannoside acyltransferase EC 2.3.1.266: [ribosomal protein S18]-alanine N-acetyltransferase EC 2.3.1.267: [ribosomal protein S5]-alanine N-acetyltransferase EC 2.3.1.268: ethanol O-acetyltransferase EC 2.3.1.269: apolipoprotein N-acyltransferase EC 2.3.1.270: lyso-ornithine lipid O-acyltransferase EC 2.3.1.271: L-glutamate-5-semialdehyde N-acetyltransferase EC 2.3.1.272: 2-acetylphloroglucinol acetyltransferase EC 2.3.1.273: diglucosylglycerate octanoyltransferase EC 2.3.1.274: phosphate acyltransferase EC 2.3.1.275: acyl phosphate:glycerol-3-phosphate acyltransferase EC 2.3.1.276: galactosamine-1-phosphate N-acetyltransferase EC 2.3.1.277: 2-oxo-3-(phosphooxy)propyl 3-oxoalkanoate synthase EC 2.3.1.278: mycolipenoyl-CoA—2-(long-chain-fatty acyl)-trehalose mycolipenoyltransferase EC 2.3.1.279: long-chain-acyl-CoA—trehalose acyltransferase EC 2.3.1.280: (aminoalkyl)phosphonate N-acetyltransferase EC 2.3.1.281: 5-hydroxydodecatetraenal polyketide synthase EC 2.3.1.282: phenolphthiocerol/phthiocerol/phthiodiolone dimycocerosyl transferase EC 2.3.1.283: 2′-acyl-2-O-sulfo-trehalose (hydroxy)phthioceranyltransferase EC 2.3.1.284: 3′-(hydroxy)phthioceranyl-2′-palmitoyl(stearoyl)-2-O-sulfo-trehalose (hydroxy)phthioceranyltransferase EC 2.3.1.285: (13S,14R)-1,13-dihydroxy-N-methylcanadine 13-O-acetyltransferase EC 2.3.1.286: protein acetyllysine N-acetyltransferase EC 2.3.1.287: phthioceranic/hydroxyphthioceranic acid synthase EC 2.3.1.288: 2-O-sulfo trehalose long-chain-acyltransferase EC 2.3.1.289: aureothin polyketide synthase system EC 2.3.1.290: spectinabilin polyketide synthase system EC 2.3.1.291: sphingoid base N-palmitoyltransferase EC 2.3.1.292: (phenol)carboxyphthiodiolenone synthase EC 2.3.1.293: meromycolic acid 3-oxoacyl-(acyl carrier protein) synthase I EC 2.3.1.294: meromycolic acid 3-oxoacyl-(acyl carrier protein) synthase II EC 2.3.1.295: mycoketide-CoA synthase EC 2.3.1.296: ω-hydroxyceramide transacylase EC 2.3.1.297: very-long-chain ceramide synthase EC 2.3.1.298: ultra-long-chain ceramide synthase EC 2.3.1.299: sphingoid base N-stearoyltransferase EC 2.3.1.300: branched-chain β-ketoacyl-[acyl-carrier-protein] synthase EC 2.3.1.301: mycobacterial β-ketoacyl-[acyl carrier protein] synthase III EC 2.3.1.302: hydroxycinnamoyl-CoA:5-hydroxyanthranilate N-hydroxycinnamoyltransferase EC 2.3.1.303: α-L-Rha-(1→2)-α-D-Man-(1→2)-α-D-Man-(1→3)-α-D-Gal-PP-Und 2IV-O-acetyltransferase EC 2.3.1.304: poly[(S)-3-hydroxyalkanoate] polymerase
Sources: en.wikipedia.org
He progressed to the quarterfinals after winning over Jaume Munar of Spain, Tomáš Macháč of Czech Republic, and Alexei Popyrin of Australia, all in straight sets. He was defeated in the quarterfinals by eventual bronze medalist Lorenzo Musetti of Italy in straight sets. In the American hard court swing, Zverev reached the quarterfinals in Montréal, losing to Sebastian Korda in three sets. He went on to defend his semifinal points in Cincinnati, losing to Jannik Sinner in an attritive three-set match. At the US Open, he reached the quarterfinals without facing a seeded opponent, with wins over lucky loser Maximilian Marterer, wildcard Alexandre Müller, Tomás Martín Etcheverry and Brandon Nakashima — his 450th career win. With that milestone, he became the second player born in the 1990s, after Grigor Dimitrov, to reach 450 ATP wins. With the win, he qualified for his seventh appearance at the 2024 ATP Finals. Zverev lost in the quarterfinals to Taylor Fritz. At the Paris Masters, Zverev defeated Tallon Griekspoor, Arthur Fils, and Stefanos Tsitsipas to set up a semifinal clash with former champion Holger Rune. He won the match in straight sets to reach the final for the second time at this event. Zverev defeated home crowd favorite Ugo Humbert in the final to clinch his second Masters title of the season and the world No. 2 ranking. Zverev won all three of his group matches at the ATP Finals to reach the semifinals, where he lost to Taylor Fritz in a deciding set tie-break.
The principal Cossack émigré leader after 1945 was Nikolai Nazarenko, the self-proclaimed president of the World Federation of the Cossack National Liberation Movement of Cossackia, who enjoyed a prominence in New York as the organizer of the annual Captive Nations parade held every July. In 1978, Nazarenko dressed in his Don Cossack uniform led the Captive Days day parade in New York city, and told a journalist: "Cossackia is a nation of 10 million people. In 1923 the Russians officially abolished Cossackia as a nation. Officially, it no longer exists...America should not spend billions supporting the Soviets with trade. We don't have to be afraid of the Russian army because half of it is made up of Captive Nations. They can never trust the rank and file". The journalist Hal McKenzie described Nazarenko as having "cut a striking figure with his white fur cap, calf-length coat with long silver-sheathed dagger and ornamental silver cartridge cases on his chest". Nazarenko was also the president of Cossack American Republican National Federation, which in turn was part of the National Republican Heritage Groups Council, and he attracted much controversy in the 1980s owing to his wartime career and certain statements he made about Jews. The American journalist Christopher Simpson in his 1988 book Blowback: America's Recruitment of Nazis and Its Effects on the Cold War called Nazarenko a leading Republican activist who made "explicit pro-Nazi, anti-semitic" statements in his speeches.
Selenium compounds commonly exist in the oxidation states −2, +2, +4, and +6. It is a nonmetal (more rarely considered a metalloid) with properties that are intermediate between the elements above and below in the periodic table, sulfur and tellurium, and also has similarities to arsenic.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.